Anal cancer is a malignancy originating in the anus—the distal opening of the gastrointestinal tract. Most commonly, it is a squamous cell carcinoma arising in the anal canal. Less frequent types include adenocarcinoma, small-cell carcinoma, and melanoma.
Understanding the distinct types of anal cancer is crucial because treatment protocols, surgical indications, and overall prognosis vary significantly across histologic classifications.
Preventive strategies have proven exceptionally effective due to the strong etiology linking anal cancer with Human Papillomavirus (HPV) infection, particularly HPV-16 and HPV-18.
Modern first-line management with combined chemoradiation therapy (CRT) offers high cure rates while preserving anal sphincter function, avoiding permanent colostomy for the majority of early to locally advanced patients.
What is Anal Cancer?
Anal cancer is a malignancy originating in the anus—the distal opening of the gastrointestinal tract (approx. 4 cm in length). Most commonly, it is a squamous cell carcinoma arising in the anal canal. Less frequent types include adenocarcinoma, small-cell carcinoma, and melanoma.
Types of Anal Cancer
Anal cancer is categorized based on the type of cells from which it originates:
• Squamous Cell Carcinoma (SCC): Most common type (about 85–90% of all cases). It arises from squamous epithelial cells lining the anal canal, often linked to Human Papillomavirus (HPV) infection (especially HPV-16). Subtypes include Keratinizing (external anal margin) and Non-keratinizing (deeper anal canal).
• Adenocarcinoma: Develops from glandular cells near anal glands or rectum (less than 10% of cases). Resembles colorectal cancer in behavior.
• Basaloid or Cloacogenic Carcinoma: Arises near the transformation zone where glandular and squamous cells meet. Considered an aggressive variant of SCC.
• Melanoma of the Anus: Rare and highly aggressive, originating from pigment-producing melanocytes. May present as a dark lump or ulcer.
• Small Cell Carcinoma / Neuroendocrine Tumors: Extremely rare and highly malignant, requiring systemic small-cell lung cancer chemotherapy protocols.
Location & Staging
Location: Occurs in the anal canal, the passage leading from rectum to external opening.
Staging: TNM system from Stage I (localized) to Stage IV (distant metastasis). German clinical data indicate 5-year survival rates: Stage I (77–90%), Stage II (67–75%), Stage IIIA/B (51–64%), and Stage IV (5–15%).
Symptoms & Red Flags
Common signs include:
1. Anal or rectal bleeding or blood in stool
2. Pain, pressure, or a felt lump/mass
3. Persistent itching, irritation, or abnormal discharge
4. Altered bowel habits, such as stool caliber or frequency changes
5. Later stages: fatigue, unexplained weight loss, or fecal incontinence
Statistics and Extent
Accounts for ~0.5% of all new cancer cases. Incidence has risen since the 1990s, particularly among women over 65 (reaching 11.4 per 100,000 in white women). Overall 5-year survival in the U.S. is approximately 68%.
Prevention of Anal Cancer
• HPV Vaccination: Protects against HPV types 16 & 18 (causing ~90% of anal cancers). Recommended for all adolescents before sexual debut, with catch-up up to age 26 (and up to age 45).
• Safe Sexual Practices: Condom use during intercourse lowers transmission risk.
• Smoking Cessation: Smoking damages mucosal epithelial cells and weakens immune defenses (smokers are 2–3X more likely to develop anal cancer).
• Screening: Regular high-resolution anoscopy (HRA) and anal Pap smears for high-risk groups (MSM, people with HIV, transplant recipients).
Diagnosis & Clinical Workup
• Digital Rectal Exam (DRE) & Anoscopy / Proctoscopy: Lighted tube inspection of mucosal lining.
• Biopsy: Gold standard for establishing histologic cancer type and grade.
• Staging Imaging: MRI Pelvis (local tumor spread & sphincters), CT Abdomen/Pelvis (lymph nodes & distant organs), PET scan, and Endoanal Ultrasound.
Treatment Options
1. Combined Chemoradiation Therapy (CRT): Standard first-line therapy using 5-fluorouracil (5-FU) and Mitomycin C (or Cisplatin) with daily radiation over 5–6 weeks. Preserves sphincter control and avoids surgery.
2. Surgery: Reserved for small superficial margin tumors or CRT treatment failure (salvage surgery). Includes Local Excision or Abdominoperineal Resection (APR requiring permanent colostomy).
3. Immunotherapy: Checkpoint inhibitors (Nivolumab, Pembrolizumab) for advanced or metastatic disease.